

# Guido BÃ¶ning

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7653362/publications.pdf>

Version: 2024-02-01

35  
papers

1,182  
citations

516710

16  
h-index

377865

34  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1689  
citing authors

#	ARTICLE	IF	CITATIONS
1	[ <sup>68</sup> Ga]DOTA-TATE PET for the detection of early transplant rejection in a heterotopic allograft heart transplantation model of the rat: a pilot study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2023, 67, .	0.7	2
2	Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. Cancers, 2022, 14, 53.	3.7	12
3	Feasibility of single-time-point dosimetry for radiopharmaceutical therapies. Journal of Nuclear Medicine, 2021, 62, jnumed.120.254656.	5.0	28
4	First Clinical Results for PSMA-Targeted $\beta$ -Therapy Using <sup>225</sup> Ac-PSMA-I&T in Advanced-mCRPC Patients. Journal of Nuclear Medicine, 2021, 62, 669-674.	5.0	87
5	Response to <sup>225</sup> Ac-PSMA-I&T after failure of long-term <sup>177</sup> Lu-PSMA RLT in mCRPC. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1262-1263.	6.4	16
6	Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup> Lu-PSMA-617 Radioligand Therapy. Diagnostics, 2021, 11, 428.	2.6	10
7	Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T. EJNMMI Physics, 2021, 8, 26.	2.7	13
8	Dosimetry and optimal scan time of [ <sup>18</sup> F]SiTATE-PET/CT in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3571-3581.	6.4	15
9	3D image-based dosimetry for Yttrium-90 radioembolization of hepatocellular carcinoma: Impact of imaging method on absorbed dose estimates. Physica Medica, 2020, 80, 317-326.	0.7	15
10	Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [ <sup>177</sup> Lu]Lu-DOTA-TATE in Lewis rats. EJNMMI Research, 2020, 10, 41.	2.5	6
11	3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT. EJNMMI Research, 2019, 9, 76.	2.5	21
12	Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments. Acta Neurochirurgica, 2019, 161, 1109-1124.	1.7	10
13	Fully Automated Production and Characterization of <sup>64</sup> Cu and Proof of Principle Small Animal PET Imaging Using <sup>64</sup> Cu-Labelled CA XII Targeting 6A10 Fab. ChemMedChem, 2018, 13, 1230-1237.	3.2	12
14	Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Research, 2018, 8, 76.	2.5	19
15	Voxel-wise analysis of dynamic <sup>18</sup> F-FET PET: a novel approach for non-invasive glioma characterisation. EJNMMI Research, 2018, 8, 91.	2.5	20
16	TSPO imaging using the novel PET ligand [ <sup>18</sup> F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Research, 2017, 7, 89.	2.5	55
17	O-(2-[ <sup>18</sup> F]fluoroethyl)-l-tyrosine PET in gliomas: influence of data processing in different centres. EJNMMI Research, 2017, 7, 64.	2.5	14
18	Preliminary experience with dosimetry, response and patient reported outcome after <sup>177</sup> Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget, 2017, 8, 3581-3590.	1.8	172

#	ARTICLE	IF	CITATIONS
19	Monitoring of Tumor Growth with [ <sup>18</sup> F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches. <i>Frontiers in Neuroscience</i> , 2016, 10, 260.	2.8	13
20	Dosimetry for <sup>177</sup> Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 42-51.	6.4	244
21	Derivation of a respiration trigger signal in small animal list-mode PET based on respiration-induced variations of the ECG signal. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 73-83.	2.1	3
22	Mesenchymal Stem Cell-Mediated, Tumor Stroma-Targeted Radioiodine Therapy of Metastatic Colon Cancer Using the Sodium Iodide Symporter as Theranostic Gene. <i>Journal of Nuclear Medicine</i> , 2015, 56, 600-606.	5.0	66
23	The Influence of Early Measurements Onto the Estimated Kidney Dose in [ <sup>177</sup> Lu][DOTA <sub>0</sub> ,Tyr <sub>3</sub> ]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors. <i>Molecular Imaging and Biology</i> , 2015, 17, 726-734.	2.6	33
24	In Vivo Mesenchymal Stem Cell Tracking with PET Using the Dopamine Type 2 Receptor and <sup>18</sup> F-Fallypride. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1342-1347.	5.0	18
25	The mixed blessing of treating symptoms in acute vestibular failure – Evidence from a 4-aminopyridine experiment. <i>Experimental Neurology</i> , 2014, 261, 638-645.	4.1	34
26	Impact of partial volume effect correction on cerebral <sup>125</sup> I-amyloid imaging in APP-Swe mice using [ <sup>18</sup> F]-florbetaben PET. <i>NeuroImage</i> , 2014, 84, 843-853.	4.2	24
27	Erroneous cardiac ECG-gated PET list-mode trigger events can be retrospectively identified and replaced by an offline reprocessing approach: first results in rodents. <i>Physics in Medicine and Biology</i> , 2013, 58, 7937-7959.	3.0	12
28	Temporal Changes in Phosphatidylserine Expression and Glucose Metabolism after Myocardial Infarction: An in Vivo Imaging Study in Mice. <i>Molecular Imaging</i> , 2012, 11, 7290.2012.00010.	1.4	12
29	Compensation for cranial spill-in into the cerebellum improves quantitation of striatal dopamine D <sub>2/3</sub> receptors in rats with prolonged [ <sup>18</sup> F]-DMFP infusions. <i>Synapse</i> , 2012, 66, 705-713.	1.2	9
30	Endogenous competition against binding of [ <sup>18</sup> F]DMFP and [ <sup>18</sup> F]fallypride to dopamine D <sub>2/3</sub> receptors in brain of living mouse. <i>Synapse</i> , 2010, 64, 313-322.	1.2	44
31	± <sub>2</sub> -Adrenergic drugs modulate the binding of [ <sup>18</sup> F]fallypride to dopamine D <sub>2/3</sub> receptors in striatum of living mouse. <i>Synapse</i> , 2010, 64, 654-657.	1.2	7
32	The Value of the Dopamine D <sub>2/3</sub> Receptor Ligand <sup>18</sup> F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes. <i>Journal of Nuclear Medicine</i> , 2010, 51, 581-587.	5.0	51
33	Validation of the Octamouse for Simultaneous <sup>18</sup> F-Fallypride Small-Animal PET Recordings from 8 Mice. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1576-1583.	5.0	24
34	Uptake and binding of the serotonin 5-HT <sub>1A</sub> antagonist [ <sup>18</sup> F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. <i>NeuroImage</i> , 2010, 49, 1406-1415.	4.2	47
35	Gaze-aligned head-mounted camera with pan, tilt, and roll motion control for medical documentation and teaching applications. , 2006, , .		11